Granowitz sez. "The population being studied in REDUCE-IT with well-controlled bad cholesterol, but other CV risk factors and without potential benefits of Vascepa"
How is this not the placebo rate .....they aren't on Vascepa ?
I'm not trying to confuse anyone ( can't say the same for your post ) ......and guess that R-IT will show modest benefit ..in the population studied .
My main complaint is that IMHO they should have mandated prior event , PCI / CABG with TG's over 200 and HDL under 40 ...from day one for inclusion in this trial .